Enanta Pharmaceuticals, Inc. - Common Stock (ENTA)
7.2900
+0.0600 (0.83%)
Enanta Pharmaceuticals is a biotechnology company focused on discovering and developing innovative therapies for infectious diseases and liver diseases
The company specializes in the research and development of small molecule drugs, primarily targeting viral infections such as hepatitis B and hepatitis C, as well as other serious medical conditions. Enanta collaborates with pharmaceutical partners to advance its pipeline of novel antiviral therapeutics, aiming to address unmet medical needs and improve patient outcomes through its scientific expertise and commitment to drug development.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the ’953 Patent”) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets).
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population. The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo. Additionally, a rapid and robust virologic effect was observed in a prespecified subset of patients who were randomized within 3 days of symptom onset, with a 1.2 log decline in viral load at Day 5 compared to placebo. The study also showed that zelicapavir demonstrated a favorable safety profile and was well-tolerated in this pediatric population. Zelicapavir, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel N-protein inhibitor in development as a once-daily oral treatment for RSV.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and well-tolerated and achieved an 85-87% reduction in viral load area under the curve (AUC) by qRT-PCR (p<0.0001), a 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001), and a 66-78% reduction of total clinical symptoms score AUC (p<0.0001) compared to placebo. EDP-323, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel L-protein inhibitor in development as a once-daily oral treatment for RSV.
Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September:
